Lv41
800 积分 2020-12-01 加入
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
1小时前
待确认
Frailty, Mortality, and Healthcare Utilization after Liver Transplantation: From the Multi‐Center Functional Assessment in Liver Transplantation (FrAILT) Study
17天前
已完结
Liver transplantation provides survival benefit at all levels of frailty: From the Multicenter Functional Assessment in Liver Transplantation Study
17天前
已完结
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease
19天前
已完结
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
1个月前
已完结
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
DC Bead: In Vitro Characterization of a Drug-delivery Device for Transarterial Chemoembolization
1个月前
已完结
Hepatocellular carcinoma
1个月前
已完结
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma
1个月前
已完结
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
1个月前
已完结
皖公网安备34019202002308
